Elan 2Q11 2Q Revenues: $333.5 million (+24%) 2Q Loss: $47.1 million (loss of $217.9 million in 2Q10) YTD Revenues: $646.5 million (+12%) YTD Loss: $21.1 million (loss of $224.7 million YTD10) Comments: Revenue from the BioNeurology business grew 27% in the quarter to $270.6 million, driven by recorded sales of Tysabri, which were up 30% to $269.3 million. Revenue from Elan Drug Technologies (EDT) business was up 12% to $62.9 million in the quarter, driven by increased Ampyra revenues and ma...